Sina Bavari

Sina Bavari was appointed Executive Vice President, Infectious Disease Research and Development in July 2022. In this role, he is responsible for leading Tonix’s development of its growing infectious disease pipeline and serves as a key member of the Company’s executive leadership team. Dr. Bavari is based in Frederick, Maryland and, as part of his role, will oversee scientific development at Tonix’s Infectious Disease R&D Center (RDC) located there.

Dr. Bavari has a record of achievement utilizing new and complex technologies and in guiding programs through clinical decision points into advanced development. He is an inventor of approximately 30 patents, published over 300 peer-reviewed manuscripts and contributed to over 40 vaccine and therapeutic development candidates, as well as numerous Investigational New Drug candidate filings. Most recently, he served as Chief Scientific Officer / Scientific Director at the U.S. Army Research Institute of Infectious Diseases (USAMRIID) and has held numerous leadership roles at USAMRIID, including Chief, Molecular and Translational Sciences Division and Therapeutic Discovery Center; Chief, Target Discovery & Experimental Microbiology, Integrated Toxicology Division; and Chief, Immunology, Target Identification, and Translational Research, Bacteriology Division.

Dr. Bavari earned his Ph.D. in Immunotoxicology and Pharmaceutical Science at the University of Nebraska Medical Center in Omaha, Nebraska, and his M.S. in Nuclear Physics and Nuclear Pharmacy at the University of Southern California, Los Angeles.